NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
05/19/2026
Back to search
Official data from USPTO
ADIPEARL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ADIPEARL
ST13
US500000098610045Class
1, 5, 10
Filing
98610045
Registration
8073554
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
05/19/2026
Trademark type
Word
Nice classes
1, 5, 10
Filing date
06/20/2024
Registration date
12/23/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/23/2025
Last transaction
05/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Epalinges, CH
Examiner
GULIANO, ROBERT N
Current location
Historical data usage
Holders and representatives
Holders
Volumina Medical SA
Representatives
Amy C. Ziegler GREER, BURNS & CRAIN LTD.
Technical classification
Nice Classes
Class 1Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical polymers for use in the manufacture of pharmaceutical preparations and medical implants; biodegradable polymer compositions for use in the manufacture of pharmaceutical preparations and medical implants
Class 5
Pharmaceutical preparationsin particular for tissue enhancement and reconstructionfor treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for aesthetic medicinefor reconstructive medicine and for reconstructive surgery; medical and veterinary preparations and articlesin particular medical and veterinary preparations for treating the loss of soft tissue volume as well as for improving skin quality and volume contours in dermatology for tissue enhancement and reconstruction; pre-filled syringes filled with pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for medical purposes; Pre-filled vials filled with pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for medical and aesthetic medicine purposes; vials and syringespre-filled with a medical preparation for enabling cellular or tissular assembly for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for aesthetic and medical purposes; injectable dermal fillers; biological implantsimplants comprising living tissue; implantable medicines for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology; injectable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans for tissue repairenhancementcreation or regeneration; implantable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans containing an anaesthetic agent or a pharmaceutical ingredient; injectable materials in the nature of injectable gels for treating the loss of soft tissue volume in humans containing an anaesthetic agent or a pharmaceutical ingredient; none of the aforementioned in relation to medication and drugs for preventingcuring or slowing down the progression of cancer; polysaccharide compositions in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for use in the dermal filler industry; polymeric biomaterialsin particular polymeric biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology for use in the cell therapy industry; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatologyin particular for use in aesthetic medicineaesthetic surgeryreconstructive surgery; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology in the form of microgels; injectable biomaterials in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contours in dermatology in the form of particlesin the form of paste or puttyin the form of a dry material; implantable biomaterials in the nature of pharmaceutical preparations for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contoursin particular for enhancing or creating new skin volumes or skin layersin the form of three-dimensional volumes; injectable biocompatible material in the nature of injectable gels for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contoursin particular for enhancing or creating new skin volumes or skin layersin dermatology used for tissues in particular soft tissues
Class 10
Surgical apparatus and instruments; prosthetic and filling materialsnamely artificial materials for use in the replacement of soft tissue in humansartificial implants; artificial breast implants; medical implants made of artificial materials; biodegradable implants consisting of artificial materials; scaffolding material for the use of three-dimensional shapeable body implantsimplantable scaffolds comprising artificial materials for creating new tissue volume or to compensate for tissue volume loss and serving as a scaffold for the regeneration of human tissue; artificial materials for the repair and enhancement of human tissueimplantable scaffolds comprising artificial materials for creating new tissue volume or to compensate for tissue volume loss and serving as a scaffold for the regeneration of human tissue; suture materials; syringes for injections; syringesvialscontainers and sterile bags sold together as medical apparatus for preparing a cellular or tissular constructfor preparing a pharmaceutical compositionfor mixing the composition with an anesthetic agent for treating the loss of soft tissue volume in humans as well as for improving skin quality and volume contoursin particular for enhancing or creating new skin volumes or skin layers in dermatology or plastic surgery for use in the dermal filler industry or tissue reconstruction and enhancement industryin the regenerative medicine industry; medical injection syringes; syringes for medical use; medical syringes for use in aesthetic surgeryin particularin dermatology and reconstructive surgery; pharmaceutical implants made of artificial materials; implants made of artificial materials for guided tissue regeneration.
Publications
History of USPTO decisions and trademark events.
34 publications found
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
04/27/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/27/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/17/2026
ES7R
TEAS SECTION 7 REQUEST RECEIVED
01/15/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/23/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/23/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2025
PUBO
PUBLISHED FOR OPPOSITION
11/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/29/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
09/15/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/15/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
09/15/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/15/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
07/10/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
07/10/2025
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
04/15/2025
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
04/15/2025
EPEN
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
04/15/2025
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
04/15/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/27/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/27/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/14/2025
GNRT
NON-FINAL ACTION E-MAILED
01/14/2025
CNRT
NON-FINAL ACTION WRITTEN
01/14/2025
DOCK
ASSIGNED TO EXAMINER
01/14/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/13/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/24/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/24/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/24/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/24/2024
NWAP
NEW APPLICATION ENTERED
06/20/2024
Continuous trademark protection
Get notified about every new filing that threatens ADIPEARL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.